BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences business.

Becton Dickinson (BDX) stock slid 3% after the company released its fiscal Q1 earnings report and confirmed it was splitting the company into two separate entities.

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $3.43 in the first ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...

In keeping with the trend in med tech to return to basics, Becton, Dickinson and Co. plans to split off its biosciences and diagnostic solutions unit to create two pure-play companies. The ‘New BD’ or ...

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.